All patients
stage IIIa stage IIIb stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - NA - all population, Ipilimumab (10 mg/kg) vs. nivolumab alone, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 238, 2017 (REV) 1.15 [0.87; 1.51]
1.15 [0.87 ; 1.51 ] CheckMate 238, 2017 (REV) 1 0% 906 NA not evaluable MFSdetailed results CheckMate 238, 2017 (REV) 1.37 [1.04; 1.80]
1.37 [1.04 ; 1.80 ] CheckMate 238, 2017 (REV) 1 0% 735 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 (REV) 1.41 [1.18; 1.69]
1.41 [1.18 ; 1.69 ] CheckMate 238, 2017 (REV) 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 (REV) 1.54 [1.21; 1.96]
1.54 [1.21 ; 1.96 ] CheckMate 238, 2017 (REV) 1 0% 906 NA not evaluable AE (any grade)detailed results CheckMate 238, 2017 (REV) 2.04 [0.81; 5.09]
2.04 [0.81 ; 5.09 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 3.61 [2.72; 4.78]
3.61 [2.72 ; 4.78 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 (REV) 6.88 [4.79; 9.89]
6.88 [4.79 ; 9.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 (REV) 9.18 [5.67; 14.85]
9.18 [5.67 ; 14.85 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable TRAE (any grade)detailed results CheckMate 238, 2017 (REV) 3.98 [2.35; 6.74]
3.98 [2.35 ; 6.74 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 5.05 [3.67; 6.97]
5.05 [3.67 ; 6.97 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 238, 2017 (REV) 4.00 [0.18; 89.05]
4.00 [0.18 ; 89.05 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 238, 2017 (REV) 8.53 [5.76; 12.63]
8.53 [5.76 ; 12.63 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 238, 2017 (REV) 11.69 [6.83; 20.02]
11.69 [6.83 ; 20.02 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.07; 59.70]
2.00 [0.07 ; 59.70 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.37; 11.00]
2.00 [0.37 ; 11.00 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.18; 22.14]
2.00 [0.18 ; 22.14 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 4.02 [0.45; 36.09]
4.02 [0.45 ; 36.09 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 6.67 [2.97; 14.99]
6.67 [2.97 ; 14.99 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.37; 11.00]
2.00 [0.37 ; 11.00 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 9.92 [4.91; 20.07]
9.92 [4.91 ; 20.07 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 7.08 [0.87; 57.77]
7.08 [0.87 ; 57.77 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 6.73 [3.15; 14.39]
6.73 [3.15 ; 14.39 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 1.00 [0.06; 16.00]
1.00 [0.06 ; 16.00 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 5.60 [1.23; 25.41]
5.60 [1.23 ; 25.41 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.00 [0.18; 22.14]
2.00 [0.18 ; 22.14 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 9.85 [2.28; 42.54]
9.85 [2.28 ; 42.54 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 5.44 [2.07; 14.31]
5.44 [2.07 ; 14.31 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 18.30 [1.06; 316.70]
18.30 [1.06 ; 316.70 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 0.50 [0.02; 14.89]
0.50 [0.02 ; 14.89 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 10.08 [0.55; 185.02]
10.08 [0.55 ; 185.02 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 4.00 [0.18; 89.05]
4.00 [0.18 ; 89.05 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 (REV) 2.85 [1.02; 7.98]
2.85 [1.02 ; 7.98 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 1.00 [0.02; 50.40]
1.00 [0.02 ; 50.40 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 8.04 [0.42; 152.61]
8.04 [0.42 ; 152.61 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 (REV) 5.67 [2.16; 14.85]
5.67 [2.16 ; 14.85 ] CheckMate 238, 2017 (REV) 1 0% 905 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 13:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 70
- treatments: 558